country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-189657

Copy Link Print Information

NNRT-IN-18

NNRT-IN-18 is an orally active HIV-1 non-nucleoside reverse transcriptase (NNRT) inhibitor with broad-spectrum anti-HIV-1 activity. NNRT-IN-18 binds to the allosteric non-nucleoside inhibitor binding pocket and inhibits RT polymerase activity with an IC₅₀ of 0.259 μM. NNRT-IN-18 exhibits low cytotoxicity and a high selectivity index, and shows minimal inhibitory activity against major cytochrome P450 isoforms. NNRT-IN-18 retains activity against NNRTI-resistant HIV-1 mutant strains. NNRT-IN-18 can be used for research on HIV-1 infection.

For research use only. We do not sell to patients.

Formula: C₂₉H₃₅N₇O₄S
Molecular Weight:577.70

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

NNRT-IN-18 Chemical Structure

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- Parmacokinetics
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

^[1]

HIV (IIIB)

0.002 μM (EC₅₀)

All HIV Isoforms :

All Cytochrome P450 Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
MT4	EC50	0.002 μM	Antiviral activity against wild-type HIV-1 IIIB in MT-4 cells assessed as protection from HIV-1-induced cytopathogenicity by MTT assay. Antiviral activity against wild-type HIV-1 IIIB in MT-4 cells assessed as protection from HIV-1-induced cytopathogenicity by MTT assay.	acs.jmedchem.6c02358
MT4	CC₅₀	39.705 μM	Cytotoxicity against mock-infected MT-4 cells assessed as viability reduction by MTT assay. Cytotoxicity against mock-infected MT-4 cells assessed as viability reduction by MTT assay.	acs.jmedchem.6c02358
MT4	EC50	0.009 μM	Antiviral activity against HIV-1 L100I mutant in MT-4 cells assessed as protection from HIV-1-induced cytopathogenicity by MTT assay. Antiviral activity against HIV-1 L100I mutant in MT-4 cells assessed as protection from HIV-1-induced cytopathogenicity by MTT assay.	acs.jmedchem.6c02358
MT4	EC50	0.008 μM	Antiviral activity against HIV-1 K103N mutant in MT-4 cells assessed as protection from HIV-1-induced cytopathogenicity by MTT assay. Antiviral activity against HIV-1 K103N mutant in MT-4 cells assessed as protection from HIV-1-induced cytopathogenicity by MTT assay.	acs.jmedchem.6c02358
MT4	EC50	0.005 μM	Antiviral activity against HIV-1 Y181C mutant in MT-4 cells assessed as protection from HIV-1-induced cytopathogenicity by MTT assay. Antiviral activity against HIV-1 Y181C mutant in MT-4 cells assessed as protection from HIV-1-induced cytopathogenicity by MTT assay.	acs.jmedchem.6c02358
MT4	EC50	0.035 μM	Antiviral activity against HIV-1 Y188L mutant in MT-4 cells assessed as protection from HIV-1-induced cytopathogenicity by MTT assay. Antiviral activity against HIV-1 Y188L mutant in MT-4 cells assessed as protection from HIV-1-induced cytopathogenicity by MTT assay.	acs.jmedchem.6c02358
MT4	EC50	0.004 μM	Antiviral activity against HIV-1 E138K mutant in MT-4 cells assessed as protection from HIV-1-induced cytopathogenicity by MTT assay. Antiviral activity against HIV-1 E138K mutant in MT-4 cells assessed as protection from HIV-1-induced cytopathogenicity by MTT assay.	acs.jmedchem.6c02358
MT4	EC50	0.030 μM	Antiviral activity against HIV-1 F227L+V106A mutant in MT-4 cells assessed as protection from HIV-1-induced cytopathogenicity by MTT assay. Antiviral activity against HIV-1 F227L+V106A mutant in MT-4 cells assessed as protection from HIV-1-induced cytopathogenicity by MTT assay.	acs.jmedchem.6c02358

In Vitro

Viral InfectionOthers

Viral Infection

NNRT-IN-18 (compound 9n) inhibits wild-type HIV-1 IIIB in MT-4 cells with EC₅₀ = 0.002 μM and CC₅₀ = 39.705 μM, and maintains single-digit nanomolar to low nanomolar EC₅₀ values against L100I, K103N, Y181C, Y188L, E138K, F227L/V106A, and RES056 mutant strains^[1].
NNRT-IN-18 inhibits wild-type HIV-1 reverse transcriptase in a cell-free ELISA enzyme assay with IC₅₀ = 0.259 μM^[1].

Others

NNRT-IN-18 exhibits low CYP inhibition, with an IC₅₀ ≥22.3 μM against CYP2D6 and IC₅₀ >25 μM against CYP1A2, CYP2C19, CYP2C9, CYP3A4-M, and CYP3A4-T^[1].
NNRT-IN-18 exhibits species-dependent hepatic microsomal stability^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Related Protocols :

Parmacokinetics

Species	Dose	Route	C_max	T_max	T_1/2	AUC_0-t	AUC_0-∞	MRT_0-t	MRT_0-∞	CL	F
Rat^[1]	1 mg/kg	i.v.	293.000 ng/mL	0.083 h	2.267 h	133.157 ng/mL·h	136.596 ng/mL·h	0.803 h	1.075 h	7337.264 mL/h/kg	/
Rat^[1]	10 mg/kg	p.o.	39.667 ng/mL	0.500 h	1.946 h	98.070 ng/mL·h	104.664 ng/mL·h	2.471 h	3.054 h	/	7.66 %

Chemical Information

Molecular Weight 577.70
Formula C₂₉H₃₅N₇O₄S
SMILES

CC1=CC(C#N)=CC(C)=C1OC2=CC(N3CCC(O)C3)=NC(NC4CCN(CC5=CC=C(S(=O)(N)=O)C=C5)CC4)=N2
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Zhang Y J, et al. Targeting the HIV-1 NNRTI Entrance Channel: Structure-Guided Optimization for Enhanced Safety and Selectivity. Journal of Medicinal Chemistry. 2026;69(18):21522-21537.

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote

Amount: USD 0.00

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
Chemical Information
Purity & Documentation
References

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

NNRT-IN-18

All HIV Isoforms

All Cytochrome P450 Isoforms